• Strengthens management team
• Plans for next stage of development
• Establishes US presence

MELBOURNE, VICTORIA, 30th November 2011: Pharmaceutical company Hatchtech Pty Ltd is pleased to announce the appointment of Mr. Timothy Waugh as Chief Executive Officer.

Tim is a senior pharmaceutical executive with extensive general management, drug development and commercial experience, particularly in the US and Europe.  Tim has worked for 27 years in the Pharmaceutical industry and has spent the last 10 years with Roche in the US as a divisional Vice President.

Paul Kelly, Hatchtech’s Chairman said “Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercializing DeOvo™ for the global marketplace.”

Tim Waugh added “I am excited to be joining Hatchtech at this pivotal stage of its growth.  DeOvo™ is positioned to be a game-changing product in the treatment of human head lice infestations, offering the potential for a simple single-application treatment.  I look forward to working with the Board and management team as we review the results of the Phase 2b study and plan for the next stages of clinical development in the coming months.”

Tim will join the Board of Hatchtech and be based in New Jersey, USA.

Company Contact
Dr Paul Kelly
Chairman
+61 (2) 8205-7379
pkelly@one-ventures.com

Read the full Media Release: News Release Appoint CEO November 2011